Company Profiles

driven by the PitchBook Platform

F2G

Description

Developer of drugs to treat life threatening fungal disease. The company develops novel antifungal drugs to treat serious, life-threatening fungal infections.

1998

Founded

PRIVATE

Status

11-50

Employees

Series E

Latest Deal Type

$60M

Latest Deal Amount

$119M

Total Amount Raised

Description

Developer of drugs to treat life threatening fungal disease. The company develops novel antifungal drugs to treat serious, life-threatening fungal infections.

Website:

www.f2g.com

Formerly Known As

Functional Fungal Genomics

Ownership Status

Privately held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

Lankro Way Eccles Manchester M30 0LXEngland +44 (0)16 1785 1270
Request a free trial to the PitchBook Platform
You're viewing a free company profile from the PitchBook Platform. To explore F2G's full profile, request a free trial.

F2G Valuation and Funding

Request access
Deal TypeDateAmountRaised to DatePost-ValStatusStage

F2G Cap Table

Stock# of Shares
Authorized
Par ValueDividend Rate (%)Original
Issue Price
LiquidationLiquidation
Pref. Multiple
Conversion
Price
% Owned

F2G Investors (13)

Request access
Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
Seat
Contact
Info
Advent Life SciencesVenture CapitalMinority000 0000000 0000
Aisling CapitalVenture CapitalMinority000 0000000 0000
Astellas Venture ManagementCorporate Venture CapitalMinority000 0000000 0000
BankInvest Biotech VenturesVenture CapitalMinority000 0000000 0000
Brace Pharma CapitalOtherMinority000 0000000 0000
Advent Life Sciences Venture Capital
Aisling Capital Venture Capital
Astellas Venture Management Corporate Venture Capital
BankInvest Biotech Ventures Venture Capital
Brace Pharma Capital Other

F2G Executive Team (9)

NameTitleBoard
Seat
Contact
Info
Ian NicholsonBoard Member & Chief Executive Officer
Ralf SchmidChief Financial Officer
Mike Birch Ph.DChief Operating Officer
Tony KennedyChief Scientific and Development Officer
Jason Oliver Ph.DHead of Biochemistry and Molecular Biology
Ian Nicholson Board Member & Chief Executive Officer
Ralf Schmid Chief Financial Officer
Mike Birch Ph.D Chief Operating Officer
Tony Kennedy Chief Scientific and Development Officer
Jason Oliver Ph.D Head of Biochemistry and Molecular Biology

F2G Board Members (10)

NameRepresentingRoleSinceContact
Info
Anja König Ph.DNovartis Venture FundsManaging Director000 0000
Christopher WrightMerifin Capital GroupDirector, London000 0000
Ian NicholsonF2GBoard Member & Chief Executive Officer000 0000
John Rex MDF2GBoard Member & Chief Medical Officer000 0000
Kaasim MahmoodAdvent Life SciencesGeneral Partner000 0000
Anja König Ph.D Managing Director Novartis Venture Funds
Christopher Wright Director, London Merifin Capital Group
Ian Nicholson Board Member & Chief Executive Officer F2G
John Rex MD Board Member & Chief Medical Officer F2G
Kaasim Mahmood General Partner Advent Life Sciences
Request full access to PitchBook